The Basics
Ketamine is a dissociative anesthetic used in medical settings since 1970. Racemic ketamine is FDA-approved as an anesthetic and is also prescribed off-label in some settings. Esketamine nasal spray (Spravato) has separate FDA-approved psychiatric indications and safety requirements. Research beginning in the late 1990s and early 2000s drew attention to ketamine's rapid antidepressant effects in some patients.
Unlike classical psychedelics that primarily target serotonin receptors, ketamine works primarily by blocking NMDA glutamate receptors. At sub-anesthetic doses, it produces altered states of consciousness that can include dissociation from the body, profound shifts in perspective, and sometimes mystical or transcendent experiences.
Key Facts
- •Class: Dissociative anesthetic (arylcyclohexylamine)
- •Timing: Onset and duration vary substantially by formulation, route, dose, redosing, health, and other substances.
- •Primary mechanism: NMDA receptor antagonism, glutamate modulation
- •Legal status: Schedule III — available via prescription for off-label use; esketamine (Spravato) FDA-approved for treatment-resistant depression
How Ketamine Works
Ketamine's antidepressant mechanism is fundamentally different from traditional antidepressants. While SSRIs take weeks to build up and primarily target serotonin, ketamine works rapidly through the glutamate system — the brain's primary excitatory neurotransmitter system.
Research links NMDA-receptor blockade and downstream glutamate signaling to changes involving AMPA receptors, BDNF, and synaptic plasticity. These proposed mechanisms are still being studied and do not guarantee that an individual will respond or that benefits will last.
Whether dissociation itself contributes to antidepressant benefit remains unsettled. Some studies report associations between aspects of the experience and outcomes, while others do not. A more intense dissociative experience should not be treated as evidence of a better or safer treatment.
Routes of Administration
Medical ketamine and esketamine are administered through several routes. Absorption, onset, monitoring, and evidence differ by formulation and route, so figures from one route cannot safely be converted into instructions for another:
- •Intravenous (IV) racemic ketamine: Used as an anesthetic and off-label for some psychiatric or pain treatments. Infusion protocols are prescribed and monitored by clinicians.
- •Intramuscular (IM) racemic ketamine: Used medically in selected settings. It has a rapid onset and cannot be adjusted after injection in the way an IV infusion can.
- •Intranasal esketamine (Spravato): A fixed-dose prescription product self-administered under direct supervision in a REMS-certified healthcare setting. It is not weight-based IV ketamine.
- •Compounded oral, sublingual, or intranasal ketamine: These products are not FDA-approved for psychiatric indications. Quality, absorption, monitoring, and risk can differ from FDA-approved products.
Therapeutic Applications
Evidence and regulatory status vary substantially by condition:
- •Depression: Esketamine has FDA-approved psychiatric indications. Racemic ketamine is used off-label by some clinicians, with evidence for rapid symptom reduction in some patients.
- •Suicidal thoughts: Studies report rapid short-term reductions in suicidal ideation for some patients, but ketamine does not replace emergency assessment, safety planning, or ongoing treatment.
- •Anxiety, OCD, and PTSD: These remain investigational or off-label uses. Evidence is more limited and results should not be generalized across diagnoses.
- •Pain: Ketamine is used medically for anesthesia and selected acute or chronic pain situations under specialist care.
Safety & Risks
Important Considerations
- •Dependency potential: Unlike classical psychedelics, ketamine has genuine addiction potential with regular use. Clinical protocols manage this with controlled frequency.
- •Bladder and urinary injury: Repeated exposure, especially frequent or heavy use, can cause painful and sometimes severe urinary tract damage. Urgency, frequency, blood in urine, or pain require medical evaluation.
- •Blood pressure: Temporarily increases blood pressure. Patients with uncontrolled hypertension need medical clearance.
- •Dissociation risks: The disconnection from body and environment requires a safe, supervised setting. Operating vehicles or machinery is dangerous during and after sessions.
- •Sedation and breathing: Ketamine can cause profound sedation and respiratory depression. Risk rises with alcohol, opioids, benzodiazepines, GHB, and other sedatives.
- •At-home and compounded products: These do not have Spravato's supervised REMS safeguards. A prescription does not make unsupervised use risk-free.
Get Help Now
Call 911 for slowed or abnormal breathing, blue or gray lips, inability to wake someone, seizure, collapse, severe chest pain, suspected aspiration, dangerous agitation, or serious injury. Place an unconscious breathing person on their side and follow dispatcher instructions.
In the U.S., call Poison Control at 1-800-222-1222. For suicidal thoughts or a mental-health crisis, call or text 988. If there is immediate physical danger, call 911.
Sources
Ketamine Clinics in the DMV
The Washington D.C., Maryland, and Virginia metro area has a growing number of ketamine clinics. When evaluating a clinic, consider:
- •Is the clinic run by a board-certified psychiatrist or anesthesiologist?
- •Do they include therapy/integration sessions alongside ketamine administration?
- •What is their screening process for medical and psychiatric contraindications?
- •Do they have protocols for managing adverse reactions?
- •How do they measure outcomes and adjust treatment plans?
See our Navigating Psychedelic Therapy guide for a detailed framework for evaluating providers.